Wells Fargo & Company Ardelyx, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Ardelyx, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 884,165 shares of ARDX stock, worth $5.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
884,165
Previous 116,579
658.43%
Holding current value
$5.1 Million
Previous $851,000
669.8%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ARDX
# of Institutions
208Shares Held
144MCall Options Held
1.01MPut Options Held
1.43M-
Janus Henderson Group PLC London, X025.9MShares$150 Million0.11% of portfolio
-
Black Rock Inc. New York, NY17.6MShares$101 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.7MShares$78.8 Million0.0% of portfolio
-
State Street Corp Boston, MA12MShares$69 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C36.9MShares$39.8 Million0.06% of portfolio
About ARDELYX, INC.
- Ticker ARDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 154,636,000
- Market Cap $892M
- Description
- Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...